InsiderTrades

Form 4 for JBIO Jade Biosciences, Inc.

Accepted 2024-04-03 00:00:00 ET · period of report 2024-04-01 · accession 0001415889-24-010136 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-04-03 2024-04-01 JBIO Eldridge George A SEE REMARKS M - OptEx $2.14 +12.5K 14.5K +638% +$26.7K
D 2024-04-03 2024-04-01 JBIO Eldridge George A SEE REMARKS S - Sale+OE $31.23 -12.5K 1,960 -86% -$390.2K
D 2024-04-03 2024-04-01 JBIO Eldridge George A SEE REMARKS M - OptEx $0.00 -12.5K 15.8K -44% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-04-01 M A 12,495 $2.14 14,455 D — —
2 Common Common Stock 2024-04-01 S D 12,495 $31.23 1,960 D — — (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
3 Derivative Stock Option (Right to Buy) 2024-04-01 M D 12,495 $0.00 15,768 D $2.14 · — to 2031-04-01 12,495 Common Stock (F3) A total of 50,850 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on March 22, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.